Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2007-03-19FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc. The approval updates the drug’s labeling.
-
FDA approval · 2007-03-19FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA (levetiracetam) from UCB, Inc., updating the product labeling as described in the sub…
-
FDA label_change · 2007-01-09FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) filed by Novartis Pharmaceuticals Corporation, likely involving a labe…
-
CLINICAL_TRIALS trial_result · 2006-12-25Clinical Trial Update: Prediction of Childhood Epilepsy Outcome in Bangladesh [NA]
Clinical trial investigating prediction of epilepsy outcomes in children in Bangladesh has completed.
-
CLINICAL_TRIALS trial_result · 2006-12-22Clinical Trial Update: Ketogenic Diet for Child Epilepsy and Seizure Control [NA]
A completed clinical trial evaluated the ketogenic diet as a strategy to control seizures in children with epilepsy, including Lennox-Gastau…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2006-12-21FDA Approved: FLUDEOXYGLUCOSE F18 — Supplemental Application (THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH)
FDA approved a supplemental application for Fludeoxyglucose F18, a PET imaging radiopharmaceutical, expanding its regulatory status.
-
FDA approval · 2006-12-17FDA Approved: VALPROIC ACID — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for valproic acid submitted by Bionpharma Inc.
-
FDA approval · 2006-12-15FDA Approved: VALPROIC ACID — Supplemental Application (Xttrium Laboratories Inc.)
The FDA approved a supplemental application for valproic acid from Xttrium Laboratories Inc., updating the approved ANDA.
-
FDA label_change · 2006-12-07FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)
FDA approved a supplemental application for gabapentin—specifically a granule formulation—from Granules Pharmaceuticals Inc.
-
FDA approval · 2006-12-05FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma's supplemental application for gabapentin as a generic drug under ANDA 075350.
-
CLINICAL_TRIALS research · 2006-11-29Clinical Trial Update: Mapping of the Epileptic Brain
Clinical trial update about a study mapping the epileptic brain, sponsored by University Hospital, Grenoble, investigating epilepsy.
-
FDA approval · 2006-11-20FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
FDA approved a supplemental application for Zonegran (zonisamide) submitted by Advanz Pharma (US) Corp.
-
CLINICAL_TRIALS trial_result · 2006-11-10Clinical Trial Update: Neonatal Brain Waves After Electrocoagulation
An update on a clinical trial evaluating neonatal brain wave patterns following electrocoagulation in epilepsy.
-
FDA approval · 2006-10-19FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TOPAMAX (topiramate) submitted by Janssen Pharmaceuticals, Inc.
-
FDA approval · 2006-10-16FDA Approved: ZONISAMIDE — Original Application (Viona Pharmaceuticals Inc)
FDA approved the original application for zonisamide from Viona Pharmaceuticals Inc, enabling a generic version of zonisamide to be marketed…
-
FDA approval · 2006-10-13FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) from AbbVie. The action updates labeling to reflect the a…
-
FDA label_change · 2006-10-13FDA Approved: DEPAKOTE — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote (divalproex sodium) submitted by AbbVie Inc. This action relates to changes impleme…
-
FDA approval · 2006-10-03FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Zarontin (ethosuximide) submitted by Parke-Davis Div of Pfizer Inc, signaling an update to t…
-
FDA approval · 2006-09-25FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for LAMICTAL (lamotrigine) from GlaxoSmithKline LLC, indicating an update to the product label/inten…
-
FDA approval · 2006-09-25FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Lamictal (lamotrigine) from GlaxoSmithKline LLC, resulting in updated labeling to reflect ex…
-
FDA approval · 2006-09-13FDA Approved: PHENYTOIN SODIUM — Original Application (Acella Pharmaceuticals, LLC)
FDA approves Acella Pharmaceuticals' phenytoin sodium generic under an original ANDA for seizure disorders. This marks the introduction of a…
-
FDA approval · 2006-09-13FDA Approved: GABAPENTIN — Original Application (Advagen Pharma Ltd)
The FDA approved Advagen Pharma Ltd's Original Application for gabapentin, enabling a generic version of the anticonvulsant. The approval su…
-
CLINICAL_TRIALS research · 2006-09-12Clinical Trial Update: Second-Line Treatment Choice for Epilepsy [NA]
A clinical trial update discusses second-line treatment choices for epilepsy, but there is no phase or status information provided.
-
FDA approval · 2006-09-05FDA Approved: PHENYTOIN SODIUM — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' Original Application for Phenytoin Sodium (generic anticonvulsant).
-
FDA approval · 2006-08-24FDA Approved: GABAPENTIN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a generic gabapentin product from Sun Pharmaceutical Industries as an Original Application (ANDA). The approval makes a generic…